JP2022151440A - Agents for treating arthritis - Google Patents
Agents for treating arthritis Download PDFInfo
- Publication number
- JP2022151440A JP2022151440A JP2021081964A JP2021081964A JP2022151440A JP 2022151440 A JP2022151440 A JP 2022151440A JP 2021081964 A JP2021081964 A JP 2021081964A JP 2021081964 A JP2021081964 A JP 2021081964A JP 2022151440 A JP2022151440 A JP 2022151440A
- Authority
- JP
- Japan
- Prior art keywords
- arthritis
- agent
- agents
- treating arthritis
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010003246 arthritis Diseases 0.000 title claims abstract description 18
- 241000894006 Bacteria Species 0.000 claims abstract description 6
- 241000700605 Viruses Species 0.000 claims abstract description 6
- 230000035755 proliferation Effects 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 241000233866 Fungi Species 0.000 claims description 5
- 230000003412 degenerative effect Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims 1
- 244000045947 parasite Species 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- -1 hydrogen ions Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、関節炎の治療薬に関する。The present invention relates to therapeutic agents for arthritis.
関節炎を有効に治療する薬がない。There are no drugs that effectively treat arthritis.
関節炎の治療薬を提供することを目的とする。The purpose is to provide a therapeutic drug for arthritis.
本発明の目的を達成するため、次の構成を採用する。
関節炎の原因の一つに、細菌、ウイルス、真菌などが、血流を介して、または近くの感染部位から関節に入り、感染症を引き起こすことがあります。
変性剤を人体に投入することにより、感染症の原因である身体に侵入した細菌やウイルスや真菌などのＤＮＡとＲＮＡを壊すことにより増殖を防ぎ、関節炎の治療をする。
細菌、ウイルス、真菌などの関節炎の病原体は、核酸を持っている。
核酸とは、ＤＮＡとＲＮＡのことである。
ＤＮＡとＲＮＡは塩基間で水素結合しているが、変性剤を加えてアルカリ性にすると、水素イオンを放出するため変性し、ＤＮＡとＲＮＡの塩基間の水素結合が壊れる。
変性剤を加えてＤＮＡとＲＮＡを壊すことにより、細菌やウイルスや真菌などの増殖を防ぐことができるため、変性剤という関節炎の治療薬となる。
関節を標的とする変性剤を有効成分とするリポソーム医薬品として、人体に投与する方法もある。In order to achieve the objects of the present invention, the following configuration is adopted.
One cause of arthritis is when bacteria, viruses, or fungi enter the joint through the bloodstream or from a nearby site of infection, causing an infection.
By injecting a denaturing agent into the human body, the DNA and RNA of bacteria, viruses, fungi, etc. that have invaded the body that are the cause of infectious diseases are destroyed, thereby preventing their proliferation and treating arthritis.
Arthritic agents such as bacteria, viruses and fungi have nucleic acids.
Nucleic acids refer to DNA and RNA.
DNA and RNA are hydrogen-bonded between bases, but when a denaturing agent is added to make them alkaline, they release hydrogen ions and denature, breaking the hydrogen bond between bases of DNA and RNA.
By adding a denaturing agent to destroy DNA and RNA, it is possible to prevent the growth of bacteria, viruses, fungi, etc., so it is a therapeutic drug for arthritis called a denaturing agent.
There is also a method of administering to the human body as a liposome drug containing a joint-targeting degenerative agent as an active ingredient.
変性剤という関節炎の治療薬を人体に投与することにより、関節炎を治療する。代表的な変性剤は、尿素薬がある。Arthritis is treated by administering arthritis therapeutic agents called degenerative agents to the human body. A representative denaturant is a urea drug.
変性剤という関節炎治療薬を手術により関節に注入する。
関節を標的とする変性剤を有効成分とするリポソーム医薬品として、飲み薬として飲むか、注射により投与する。
代表的な変性剤は、尿素薬がある。An arthritis drug called a degenerative agent is surgically injected into the joint.
As a liposomal drug containing a joint-targeting degenerative agent as an active ingredient, it is taken orally or administered by injection.
A representative denaturant is a urea drug.
特願２０２０－１５５８６２Patent application 2020-155862
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081964A JP2022151440A (en) | 2021-03-26 | 2021-03-26 | Agents for treating arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021081964A JP2022151440A (en) | 2021-03-26 | 2021-03-26 | Agents for treating arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022151440A true JP2022151440A (en) | 2022-10-07 |
Family
ID=83464219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021081964A Pending JP2022151440A (en) | 2021-03-26 | 2021-03-26 | Agents for treating arthritis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2022151440A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07187935A (en) * | 1992-07-24 | 1995-07-25 | Chemosan Gmbh Erzeugung Pharmazeut Grundstoff | Methods for inactivating prionen, viruses and other infectious agents |
| JP2009526060A (en) * | 2006-02-09 | 2009-07-16 | ゴジョ・インダストリーズ・インコーポレイテッド | Antiviral method |
| JP2011231087A (en) * | 2010-04-30 | 2011-11-17 | Nihon Univ | Antiviral agent having photosensitive substance as active ingredient |
-
2021
- 2021-03-26 JP JP2021081964A patent/JP2022151440A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07187935A (en) * | 1992-07-24 | 1995-07-25 | Chemosan Gmbh Erzeugung Pharmazeut Grundstoff | Methods for inactivating prionen, viruses and other infectious agents |
| JP2009526060A (en) * | 2006-02-09 | 2009-07-16 | ゴジョ・インダストリーズ・インコーポレイテッド | Antiviral method |
| JP2011231087A (en) * | 2010-04-30 | 2011-11-17 | Nihon Univ | Antiviral agent having photosensitive substance as active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10463690B2 (en) | Method and compositions for treating cancerous tumors | |
| Eze et al. | Therapeutic effect of honey bee venom | |
| Vlassov et al. | Bacteriophages as therapeutic preparations: what restricts their application in medicine | |
| EP1666064A4 (en) | MEDICAMENT FOR TREATING DISEASES ASSOCIATED WITH TRANSLOCATION OF AN IMMUNOGLOBULIN GENE | |
| JP2022151440A (en) | Agents for treating arthritis | |
| US20120156188A1 (en) | Chemical method for sexual sterilization and libido elimination in male mammals | |
| JP2022151436A (en) | Agents for treating meningitidis and encephalitis | |
| JP2022140190A (en) | Therapeutic agent for autoimmune diseases | |
| JP2022151437A (en) | Agents for treating retinitis | |
| JP2022151430A (en) | Agents for treating cholecystitis | |
| JP2022151428A (en) | Agent for treating nephritis | |
| JP2022151439A (en) | Agents for treating rhinitis | |
| JP2022151427A (en) | Esophagitis remedy. | |
| JP2022151431A (en) | A remedy for enteritis. | |
| JP2022151438A (en) | Agents for treating conchitis and tympanitis | |
| JP2022151429A (en) | Agents for treating pancreatitis | |
| JP2022151432A (en) | Agents for treating myocarditis and pericarditis | |
| JP2022151433A (en) | Agents for treating cystitis | |
| JP2022124985A (en) | Pneumonia therapeutic drugs | |
| EP3086805B1 (en) | Use of glycyl-glycine endopeptidase for treating mycobacteria infections | |
| JP2022146828A (en) | Therapeutic agents for gastritis, gastric ulcer, and duodenal ulcer | |
| JP2022151434A (en) | Agents for treating dermatitis | |
| JP2022146830A (en) | Therapeutic agent for retinal detachment | |
| JP2022151423A (en) | Agents for treating disc herniation | |
| JP2022151426A (en) | Agents for treating upper respiratory inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210326 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210810 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220719 |